Dabur arms face lawsuits in US, Canada alleging products caused cancer

Reuters Updated - October 19, 2023 at 09:34 AM.

Dabur says allegations “unsubstantiated and incomplete”; defence costs to breach the materiality threshold

Dabur arms face lawsuits in US | Photo Credit: HANDOUT_E_MAIL

Dabur India said on Wednesday its subsidiaries were among companies sued in the U.S. and Canada by customers alleging that the use of hair relaxer products had caused ovarian cancer, uterine cancer and other health issues.

“Unsubstantiated and incomplete”: “Currently, the cases are in the pleadings and early discovery phases of litigation,” it said in an exchange filing, adding the allegations are based on “unsubstantiated and incomplete” study.

Dabur said about 5,400 cases against several companies including its subsidiaries, Namaste Laboratories, Dermoviva Skin Essentials and Dabur International, have been consolidated as a multi-district litigation before a U.S. District Court in Illinois.

The units have denied liability and have retained counsel to defend them, the company said.

Dabur India, which sells Vatika Shampoo and Honitus cough syrup brands, said it could not determine the financial implication due to settlement or verdict outcome at this stage but expected the defence costs to breach the materiality threshold in the near future.

The company did not immediately respond to a request for additional details outside of normal business hours.

Published on October 19, 2023 04:01

This is a Premium article available exclusively to our subscribers.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

You have reached your free article limit.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

You have reached your free article limit.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

TheHindu Businessline operates by its editorial values to provide you quality journalism.

This is your last free article.